• Something wrong with this record ?

Dual Targeting of BRAF and mTOR Signaling in Melanoma Cells with Pyridinyl Imidazole Compounds

V. Palušová, T. Renzová, A. Verlande, T. Vaclová, M. Medková, L. Cetlová, M. Sedláčková, H. Hříbková, I. Slaninová, M. Krutá, V. Rotrekl, H. Uhlířová, A. Křížová, R. Chmelík, P. Veselý, M. Krafčíková, L. Trantírek, KO. Schink, S. Uldrijan,

. 2020 ; 12 (6) : . [pub] 20200610

Language English Country Switzerland

Document type Journal Article

Grant support
CZ.02.1.01/0.0/0.0/16_019/0000868 European Regional Development Fund
MUNI/A/1087/2018 Masarykova Univerzita
18-01396S Grantová Agentura České Republiky
NV19-08-00450 Ministerstvo Zdravotnictví Ceské Republiky
CIISB - LM2018127 Ministerstvo Školství, Mládeže a Tělovýchovy
LM2015062 Ministerstvo Školství, Mládeže a Tělovýchovy

BRAF inhibitors can delay the progression of metastatic melanoma, but resistance usually emerges, leading to relapse. Drugs simultaneously targeting two or more pathways essential for cancer growth could slow or prevent the development of resistant clones. Here, we identified pyridinyl imidazole compounds SB202190, SB203580, and SB590885 as dual inhibitors of critical proliferative pathways in human melanoma cells bearing the V600E activating mutation of BRAF kinase. We found that the drugs simultaneously disrupt the BRAF V600E-driven extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase (MAPK) activity and the mechanistic target of rapamycin complex 1 (mTORC1) signaling in melanoma cells. Pyridinyl imidazole compounds directly inhibit BRAF V600E kinase. Moreover, they interfere with the endolysosomal compartment, promoting the accumulation of large acidic vacuole-like vesicles and dynamic changes in mTOR signaling. A transient increase in mTORC1 activity is followed by the enrichment of the Ragulator complex protein p18/LAMTOR1 at contact sites of large vesicles and delocalization of mTOR from the lysosomes. The induced disruption of the endolysosomal pathway not only disrupts mTORC1 signaling, but also renders melanoma cells sensitive to endoplasmic reticulum (ER) stress. Our findings identify new activities of pharmacologically relevant small molecule compounds and provide a biological rationale for the development of anti-melanoma therapeutics based on the pyridinyl imidazole core.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20019055
003      
CZ-PrNML
005      
20201123124541.0
007      
ta
008      
201103s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers12061516 $2 doi
035    __
$a (PubMed)32531927
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Palušová, Veronika $u Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic. International Clinical Research Center, St. Anne's University Hospital Brno, Pekařská 664/53, 656 91 Brno, Czech Republic.
245    10
$a Dual Targeting of BRAF and mTOR Signaling in Melanoma Cells with Pyridinyl Imidazole Compounds / $c V. Palušová, T. Renzová, A. Verlande, T. Vaclová, M. Medková, L. Cetlová, M. Sedláčková, H. Hříbková, I. Slaninová, M. Krutá, V. Rotrekl, H. Uhlířová, A. Křížová, R. Chmelík, P. Veselý, M. Krafčíková, L. Trantírek, KO. Schink, S. Uldrijan,
520    9_
$a BRAF inhibitors can delay the progression of metastatic melanoma, but resistance usually emerges, leading to relapse. Drugs simultaneously targeting two or more pathways essential for cancer growth could slow or prevent the development of resistant clones. Here, we identified pyridinyl imidazole compounds SB202190, SB203580, and SB590885 as dual inhibitors of critical proliferative pathways in human melanoma cells bearing the V600E activating mutation of BRAF kinase. We found that the drugs simultaneously disrupt the BRAF V600E-driven extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase (MAPK) activity and the mechanistic target of rapamycin complex 1 (mTORC1) signaling in melanoma cells. Pyridinyl imidazole compounds directly inhibit BRAF V600E kinase. Moreover, they interfere with the endolysosomal compartment, promoting the accumulation of large acidic vacuole-like vesicles and dynamic changes in mTOR signaling. A transient increase in mTORC1 activity is followed by the enrichment of the Ragulator complex protein p18/LAMTOR1 at contact sites of large vesicles and delocalization of mTOR from the lysosomes. The induced disruption of the endolysosomal pathway not only disrupts mTORC1 signaling, but also renders melanoma cells sensitive to endoplasmic reticulum (ER) stress. Our findings identify new activities of pharmacologically relevant small molecule compounds and provide a biological rationale for the development of anti-melanoma therapeutics based on the pyridinyl imidazole core.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Renzová, Tereza $u Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic.
700    1_
$a Verlande, Amandine $u Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic.
700    1_
$a Vaclová, Tereza $u Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic.
700    1_
$a Medková, Michaela $u Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic.
700    1_
$a Cetlová, Linda $u Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic.
700    1_
$a Sedláčková, Miroslava $u Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic.
700    1_
$a Hříbková, Hana $u Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic.
700    1_
$a Slaninová, Iva $u Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic.
700    1_
$a Krutá, Miriama $u Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic.
700    1_
$a Rotrekl, Vladimír $u Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic. International Clinical Research Center, St. Anne's University Hospital Brno, Pekařská 664/53, 656 91 Brno, Czech Republic.
700    1_
$a Uhlířová, Hana $u Institute of Physical Engineering, Faculty of Mechanical Engineering, Brno University of Technology, Technická 2896/2, 616 69 Brno, Czech Republic. CEITEC-Central European Institute of Technology, Brno University of Technology, Purkyňova 656/123, 612 00 Brno, Czech Republic.
700    1_
$a Křížová, Aneta $u CEITEC-Central European Institute of Technology, Brno University of Technology, Purkyňova 656/123, 612 00 Brno, Czech Republic.
700    1_
$a Chmelík, Radim $u Institute of Physical Engineering, Faculty of Mechanical Engineering, Brno University of Technology, Technická 2896/2, 616 69 Brno, Czech Republic. CEITEC-Central European Institute of Technology, Brno University of Technology, Purkyňova 656/123, 612 00 Brno, Czech Republic.
700    1_
$a Veselý, Pavel $u CEITEC-Central European Institute of Technology, Brno University of Technology, Purkyňova 656/123, 612 00 Brno, Czech Republic.
700    1_
$a Krafčíková, Michaela $u National Centre for Biomolecular Research, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic.
700    1_
$a Trantírek, Lukáš $u CEITEC-Central European Institute of Technology, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic.
700    1_
$a Schink, Kay Oliver $u Centre for Cancer Cell Reprogramming, Faculty of Medicine, University of Oslo, Montebello, N-0379 Oslo, Norway. Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Montebello, N-0379 Oslo, Norway.
700    1_
$a Uldrijan, Stjepan $u Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic. International Clinical Research Center, St. Anne's University Hospital Brno, Pekařská 664/53, 656 91 Brno, Czech Republic.
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 12, č. 6 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32531927 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201103 $b ABA008
991    __
$a 20201123124540 $b ABA008
999    __
$a ind $b bmc $g 1585835 $s 1109253
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 12 $c 6 $e 20200610 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
GRA    __
$a CZ.02.1.01/0.0/0.0/16_019/0000868 $p European Regional Development Fund
GRA    __
$a MUNI/A/1087/2018 $p Masarykova Univerzita
GRA    __
$a 18-01396S $p Grantová Agentura České Republiky
GRA    __
$a NV19-08-00450 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a CIISB - LM2018127 $p Ministerstvo Školství, Mládeže a Tělovýchovy
GRA    __
$a LM2015062 $p Ministerstvo Školství, Mládeže a Tělovýchovy
LZP    __
$a Pubmed-20201103

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...